From the Wires
MyMedicalRecords Files Patent Infringement Complaint Against Walgreens
Jan. 31, 2013 08:35 AM
LOS ANGELES, CA -- (Marketwire) -- 01/31/13 -- MyMedicalRecords, Inc. ("MMR"), a wholly owned subsidiary of MMRGlobal, Inc. (OTCQB: MMRF), today announced the filing of a complaint for patent infringement against Walgreen Co. The complaint alleges that Walgreens is infringing on MMR's Personal Health Records patent, specifically U.S. Patent No. 8,301,466, and as a result, MMR is seeking monetary damages as well as a permanent injunction. As stated in the complaint, Walgreens is the nation's largest drugstore chain with fiscal 2012 sales of $72 billion, operating 8061 drugstores and providing services to over 6 million customers. The complaint was filed in the United States District Court for the Central District of California, case number CV 13-00631, on January 29 and is available on the court's website http://www.pacer.gov/.
MMR is a leading provider of Personal Health Records (PHRs), MyEsafeDepositBox storage solutions, and MMRPro document management and imaging systems for healthcare professionals. MMR currently has seven U.S. Health IT patents: U.S. Patent Nos. 8,301,466; 8,352,287; 8,352,288; 8,121,855; 8,117,646; 8,117,045; and 8,321,240. The MMR Patent Portfolio includes nearly 400 claims as well as additional applications and continuation applications. The patents involve inventions pertaining to Personal Health Records, Patient Portals and other Electronic Health Record systems. MMR also has been granted patents and has other pending applications in countries of commercial interest including Australia, Singapore, New Zealand, Mexico, Japan, Canada, Hong Kong, South Korea, Israel, and European nations.
Working with Liner Grode Stein Yankelevitz Sunshine Regenstreif & Taylor LLP, MMR is pursuing efforts to monetize its patent portfolio and other IP by investigating potential infringement of MMR's patents by entities such as retail pharmacies, EHR and PHR vendors, laboratory systems, hospitals, physicians, and other healthcare professionals.
On January 23, 2013, BioMedReports.com published an article regarding the MMR Patents linking to a Research and Valuation report. The report discusses how more than 5500 hospitals, 150 PHR vendors and 750 EMR vendors as well as providers, payers and pharmacies are potential licensees of the MMR Patent Portfolio. The Valuation covers MMR's U.S. Patents and does not include its issued patents and pending applications in twelve additional countries. Since the publication of the report less than two weeks ago, MMR received notice of Health IT patent approvals in Japan. To go directly to the report, visit http://michaelbass.com/PDF/Patent_Valuation.pdf.
For additional information regarding the MyMedicalRecord, Inc. complaint against Walgreen Co., contact Ted Ward at Liner Grode Stein Yankelevitz Sunshine Regenstreif & Taylor LLP at (310) 500-3384.
MMRGlobal, Inc., through its wholly-owned operating subsidiary, MyMedicalRecords, Inc., provides secure and easy-to-use online Personal Health Records ("PHRs") and electronic safe deposit box storage solutions, serving consumers, healthcare professionals, employers, insurance companies, financial institutions, retail pharmacies, and professional organizations and affinity groups. The MyMedicalRecords PHR enables individuals and families to access their medical records and other important documents, such as birth certificates, passports, insurance policies and wills, anytime from anywhere using the Internet. MyMedicalRecords is built on proprietary, patented technologies to allow documents, images and voicemail messages to be transmitted and stored in the system using a variety of methods, including fax, phone, or file upload without relying on any specific electronic medical record platform to populate a user's account. The Company's professional offering, MMRPro, is designed to give physicians' offices an easy and cost-effective solution to digitizing paper-based medical records and sharing them with patients through an integrated patient portal. Through its merger with Favrille, Inc. in January 2009, the Company acquired intellectual property biotech assets that include anti-CD20 antibodies and data and samples from its FavId/Specifid vaccine clinical trials for the treatment of B-Cell Non-Hodgkin's lymphoma. To learn more about MMRGlobal, Inc. visit www.mmrglobal.com. View demos and video tutorials of the Company's products and services at www.mmrtheater.com.
All statements in this press release that are not strictly historical in nature, including, without limitation, intellectual property enforcement actions, infringement claims or litigation, intellectual property licenses, and future performance, management's expectations, beliefs, intentions, estimates or projections, constitute "forward-looking statements." Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. Some can be identified by the use of words (and their derivations) such as "need," "possibility," "potential," "intend," "offer," "development," "if," "negotiate," "when," "begun," "believe," "achieve," "will," "estimate," "expect," "maintain," "plan," and "continue," or the negative of these words. Actual outcomes and results of operations and the timing of selected events may differ materially from the results predicted, and any reported results should not be considered as an indication of future performance. Such statements are necessarily based on assumptions and estimates and are subject to various risks and uncertainties, including those relating to the possible invalidity of the underlying assumptions and estimates and possible changes or developments in economic, business, industry, market, legal and regulatory circumstances and conditions and actions taken or omitted to be taken by third parties, including customers, suppliers, business partners, potential licensees, competitors and legislative, judicial and other governmental authorities and officials. Factors that could cause or contribute to such differences include, but are not limited to: unexpected outcomes with respect to intellectual property enforcement actions, claims of intellectual property infringement and general intellectual property litigation; our ability to maintain, develop, monetize and protect our patent portfolio for both the Company's health IT and biotechnology intellectual property assets in the U.S. and internationally; research and valuation reports on the Company; the timing of milestone payments in connection with licensing our intellectual property; our ability to establish and maintain strategic relationships; changes in our relationships with our licensees; the risk the Company's products are not adopted or viewed favorably by the healthcare community and consumer retail market; business prospects, results of operations or financial condition; risks related to the current uncertainty and instability in financial and lending markets, including global economic uncertainties; the timing and volume of sales and installations; the length of sales cycles and the installation process; the market's acceptance of new product and service introductions; competitive product offerings and promotions; changes in government laws and regulations including the 2009 HITECH Act and changes in Meaningful Use and the 2010 Affordable Care Act; future changes in tax legislation and initiatives in the healthcare industry; undetected errors in our products; the possibility of interruption at our data centers; risks related to third party vendors; risks related to obtaining and integrating third-party licensed technology; risks related to a security breach by third parties; risks associated with recruitment and retention of key personnel; other litigation matters; uncertainties associated with doing business internationally across borders and territories; and additional risks discussed in the Company's filings with the Securities and Exchange Commission including disclosures about the Company's relationship with the Michael Bass Group since 2009. The Company is providing this information as of the date of this release and, except as required by applicable law, does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise.
Add to Digg Bookmark with del.icio.us Add to Newsvine